SecBot SecBot
ANALYST-UPGRADE ·Filed Jul 7, 2026

REGN

REGENERON PHARMACEUTICALS, INC.
MIXED
Impact 2/10
Horizonmonths Processed4mo ago SECanalyst-REGN-benchmar-20260707
Benchmark double upgrade: Hold → Buy
Actionable Insight ◆ Mixed

The double upgrade is a bullish catalyst, but the absurdly low $185 target undermines its credibility. Traders should wait for clarification from Benchmark or a revised target before acting on this call. The consensus bullish view and upcoming earnings on July 30 add to the uncertainty.

DirectionMixed
Confidencemedium
Horizonmonths

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$676.23
T+0 close · Jul 7, 2026 · via day close
Latest settled
+12.13%
T+60 · $758.27
Vs SPY
+10.14%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 7 $676.23entry
  2. T+1 · 4mo ago −1.97%α −1.67% · $662.88
  3. T+5 · 4mo ago −2.97%α −3.52% · $656.12
  4. T+20 · 4mo ago +12.28%α +10.94% · $759.24
  5. T+60 · 7w ago +12.13%α +10.14% · $758.27
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Benchmark double-upgraded REGN from Hold to Buy on July 7, 2026, but set a price target of $185, implying a 71.5% downside from the current $649.81, an extreme divergence from the consensus mean of $833.31. The firm's 54% accuracy on 1,703 calls is average, and its average return of 6% is in line with peers. Consensus remains heavily bullish: 71% Buy (27 of 38 analysts), 29% Hold, 0% Sell. The mean target of $833.31 offers 28.2% upside, with a high of $1,000 and low of $641. Benchmark's $185 target sits far below the lowest Street estimate. 30-day analyst momentum shows 1 upgrade and 0 downgrades, while EPS revisions are net positive for the next quarter and current year. Insider sales by Arthur F Ryan (~$51K on May 1) are small and non-informative; a congressional buy by Ro Khanna adds a minor bullish signal. The double upgrade is a strong directional call, but the contradictory price target creates confusion, traders should treat this as an outlier until clarified.

Impact Score

Base Score
2/7
LLM Adjustment
+0
Final Score
2/10

Consensus & Targets

Buy / Strong Buy
27 (71%)
Hold
11
Sell / Strong Sell
0
Total Analysts
28
Mean PT
$833.31
Median PT
$852.50
High PT
$1,000.00
Low PT
$641.00
Current Price
$649.81
Implied Upside
+28.2%

Of 38 analysts covering REGN, 9 rate it Strong Buy, 18 Buy, 11 Hold, 0 Sell, and 0 Strong Sell, a 71% Buy-side consensus. The consensus is firmly bullish, with no sell ratings. Benchmark's upgrade aligns with the majority view, but its price target is an extreme outlier.

The consensus mean price target is $833.31, median $852.50, high $1,000, and low $641. At $649.81, REGN trades 22% below the low end of the Street range. Implied upside to the mean is 28.2%. Benchmark's $185 target is 71.5% below the current price and 77.8% below the consensus low, the most bearish target by a wide margin.

Recent Analyst Activity

DateFirmActionRatingPrice Target
2026-07-07Truist SecuritiesmaintainBuy$769.00
2026-07-07BenchmarkupgradeBuy$185.00
2026-07-06HSBCmaintainBuyNo target
2026-07-06Cantor FitzgeraldmaintainOverweight$750.00
2026-05-19Canaccord GenuitymaintainBuy$875.00
2026-05-18BMO CapitalmaintainOutperform$730.00
2026-05-18Truist SecuritiesmaintainBuy$778.00
2026-05-18JP MorganmaintainOverweight$850.00
2026-05-18Piper SandlermaintainOverweight$855.00
2026-05-18Wells FargomaintainEqual-Weight$700.00

In the past 30 days, REGN has received 1 upgrade (Benchmark) and 0 downgrades. EPS revisions show a mixed but slightly positive trend: for the current quarter, 9 upward vs 11 downward revisions in 30 days; for the next quarter, 13 up vs 6 down; for the current fiscal year, 17 up vs 8 down. Estimates are being revised higher for the forward periods.

Firm Track Record: Benchmark

Benchmark accuracy: 54% on 1703 calls | avg return: 6%

Industry benchmark: mean 51% ± 11%. Top tier: ≥61% (mean + 1σ). Based on 15 firms with ≥5 scored calls.

FirmAccuracyCallsAvg Returnvs Average
UBS67%4/65.1%top tier
Canaccord Genuity57%4/79.4%above average
TD Cowen50%1/23.1%below average
Bernstein50%1/26.2%below average
Cantor Fitzgerald50%4/8-4.5%below average
BMO Capital50%3/6-3.7%below average
Morgan Stanley50%5/104.1%below average
Goldman Sachs50%1/2-3.6%below average
Leerink Partners50%1/2-23.7%below average
Evercore ISI Group50%1/2-4.9%below average

Benchmark has a 54% accuracy rate on 1,703 scored calls with an average return of 6%. This is in line with the peer average. Among firms covering REGN, UBS leads with 67% accuracy (6 calls), while RBC Capital lags at 33% (18 calls). Benchmark's track record does not suggest exceptional forecasting ability for this name.

Earnings Estimates

Next earnings: Jul 30, 2026

PeriodEPS Est.EPS RangeRevenueRevisions (7d)
0q$10.81$7.69 to $13.25$3.8B↑1 ↓0
+1q$13.07$8.88 to $17.10$4.2B↑1 ↓0
0y$46.21$37.15 to $53.61$15.9B↑2 ↓0
+1y$48.10$40.93 to $60.05$17.6B↑0 ↓0

Cross-Platform Signals

Insider Trades (90d)
0 buys / 5 sells
Congressional
Ro Khanna (democrat): buy $1,001 - $15,000
Institutional
Empowered Funds, LLC: trim (-52.8%)
Institutional
Walleye Capital LLC: near_exit (-88.7%)
Institutional
GATEWAY INVESTMENT ADVISERS LLC: add (67.9%)

Insider activity shows only sales: Arthur F Ryan sold ~$51K worth of shares on May 1, 2026, a small, routine-looking transaction with limited predictive power. A single congressional buy by Rep. Ro Khanna (Democrat, $1K-$15K) on April 13 provides a minor bullish signal. Institutional moves are mixed: Empowered Funds trimmed 52.8%, while INTECH added 33%. No short interest data is available. The analyst upgrade is not strongly corroborated by other signals.

Investment Themes

Documents Analyzed

Report based on filing metadata.

Track record

53 reports on REGN

Performance horizon

11 of 17 bullish or bearish reports moved the stock their way by T+20. Best: +31.76% at T+20 after the Oct 6, 2026 report. 17 of 21 went positive at some point.

Filters
  1. Nov 16, 2026today 144 Neutral 2/10 Entry $951.23 Now $952.40 +0.12% settles Dec 16
  2. Nov 16, 2026today 144 Neutral 2/10 Entry $948.00 Now $952.40 +0.46% settles Dec 16
  3. Nov 12, 20264d ago Press Release Bullish 5/10 Entry $955.47 Now $952.40 −0.32% settles Dec 14
  4. Nov 5, 202611d ago Insider Cluster Neutral 2/10 Entry $904.35 Now $952.40 +5.31% settles Dec 7
  5. Nov 5, 202611d ago Insider Cluster Neutral 3/10 Entry $904.35 Now $952.40 +5.31% settles Dec 7
  6. Nov 4, 202612d ago 144 Neutral 1/10 Entry $902.90 Now $952.40 +5.48% settles Dec 4
  7. Nov 4, 202612d ago 144 Neutral 2/10 Entry $902.90 Now $952.40 +5.48% settles Dec 4
  8. Nov 3, 202613d ago Insider Cluster Neutral 2/10 Entry $930.67 Now $952.40 +2.33% settles Dec 3
  9. Nov 3, 202613d ago 144 Neutral 2/10 Entry $930.67 Now $952.40 +2.33% settles Dec 3
  10. Nov 3, 202613d ago Insider Cluster Neutral 2/10 Entry $930.67 Now $952.40 +2.33% settles Dec 3
Showing 10 of 53

US Market Status

Market Closed · Opens Wed (10h 21m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 7, 2026